Influenza Virus Vaccine, Live, Trivalent Dosage
This dosage information may not include all the information needed to use Influenza Virus Vaccine, Live, Trivalent safely and effectively. See additional information for Influenza Virus Vaccine, Live, Trivalent.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Geriatric Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Influenza Prophylaxis
Adults up to 49 years: One dose (0.2 mL) intranasally per influenza season. Administer as 0.1 mL per nostril.
Usual Geriatric Dose for Influenza Prophylaxis
50 years and older: not recommend
Usual Pediatric Dose for Influenza Prophylaxis
Under 2 years of age: not recommended due to an increased risk of hospitalization and wheezing observed in clinical trials.
2 to 8 years not previously vaccinated with influenza virus vaccine nasal spray: 1 dose of 0.2 mL intranasally, followed by a second 0.2 mL dose administered at least 1 month apart.
2 to 8 years previously vaccinated with influenza virus vaccine nasal spray: 1 dose of 0.2 mL intranasally per influenza season.
9 years and over: 1 dose of 0.2 mL intranasally per influenza season.
Administer all doses as 0.1 mL per nostril.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Influenza virus vaccine, live, is intended for intranasal administration only. Do not administer parenterally.
It is contraindicated in individuals with a hypersensitivity to eggs or egg products, gentamicin, gelatin, arginine, or life-threatening reactions to previous influenza vaccination. Do not use in children and adolescents (2 to 17 years of age) receiving aspirin or aspirin-containing therapy, due to the association of Reye's syndrome with aspirin and wild-type influenza infection.
Do not use in patients with severe asthma or active wheezing. Patients with asthma or children less than 5 years of age with recurrent wheezing should not use unless benefit outweighs risk. The use in patients with a history of Guillain-Barre syndrome within 6 weeks of any prior influenza vaccination or in immunocompromised patients should be based on careful consideration of the potential benefits and risks. Safety has not been established in patients with underlying medical conditions predisposing them to wild-type influenza infection complications.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration.
Safety and effectiveness have not been studied in pregnant women or nursing mothers.
Recipients should avoid close contact, for example within the same household, with immunocompromised individuals for at least 21 day following administration of influenza virus vaccine, live.
Postpone administration until after the acute phase, typically 72 hours, of febrile and/or respiratory illnesses.
There are no data on the safety and efficacy of influenza virus vaccine, live, when administered concurrently with antiviral compounds which have activity against influenza A and/or B viruses. Therefore, the manufacturer recommends postponing administration of influenza virus vaccine, live, until at least 48 hours after the cessation of antiviral therapy and to avoid initiation of antiviral therapy until at least 2 weeks after administration of influenza virus vaccine, live, unless medically indicated.
There are no data on the safety and efficacy of concomitant nasal administration of influenza virus, live, and other intranasal medications.
There are no data on the safety and immunogenicity of administration of influenza virus vaccine, live, and other vaccines; therefore, the manufacturer recommends concomitant administration only if benefit outweighs risk.
Nasopharyngeal secretions or swabs may test positive for influenza virus for up to 21 days following nasal administration of influenza virus vaccine, live.
Data not available
Administer vaccine prior to exposure to influenza. It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available and if possible, prior to October. However, vaccination should continue throughout the influenza season as long as vaccine is available. For children ages 2 to 8 years who have never received influenza vaccine, vaccinate in October or earlier since a second dose will need to be given one month after the initial dose.